SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences - Quaterly Results

29 Oct 2021 Evaluate
The revenue for the September 2021 quarter is pegged at Rs. 1126.50 millions, about 15.98% up against Rs. 971.30 millions recorded during the year-ago period.Net Profit recorded in the quarter ended September 2021 rise to 41.26% to Rs. 157.50  millions  compared to R. 111.50 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 265.10 millions from 191.60 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 1126.50 971.30 15.98 2207.80 1887.80 16.95 3891.40 3755.70 3.61
Other Income 7.10 0.40 1675.00 11.20 4.90 128.57 9.10 7.30 24.66
PBIDT 265.10 191.60 38.36 498.70 364.60 36.78 708.40 598.80 18.30
Interest 1.70 2.30 -26.09 3.00 5.40 -44.44 7.90 17.50 -54.86
PBDT 263.40 189.30 39.14 495.70 359.20 38.00 700.50 528.10 32.65
Depreciation 39.90 42.00 -5.00 79.50 83.60 -4.90 164.70 163.60 0.67
PBT 223.50 147.30 51.73 416.20 275.60 51.02 535.80 364.50 47.00
TAX 66.00 35.80 84.36 122.90 73.50 67.21 135.80 74.40 82.53
Deferred Tax -1.00 -11.50 -91.30 -1.90 -14.90 -87.25 -35.70 -26.60 34.21
PAT 157.50 111.50 41.26 293.30 202.10 45.13 400.00 290.10 37.88
Equity 132.30 132.30 0.00 132.30 132.30 0.00 132.30 132.30 0.00
PBIDTM(%) 23.53 19.73 19.30 22.59 19.31 16.95 18.20 15.94 14.18

RPG Life Sciences Share Price

2010.60 36.30 (1.84%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×